Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap

GB Frisoni, D Perani, S Bastianello, G Bernardi, C Porteri, M Boccardi, SF Cappa, Marco Trabucchi, Alessandro Padovani

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries. © 2016 Elsevier Inc.
Original languageEnglish
Pages (from-to)119-131
Number of pages13
JournalNeurobiology of Aging
Volume52
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Alzheimer Disease
Biomarkers
Amyloidosis
Advisory Committees
Morbidity
Mortality
Brain
Population

Cite this

Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. / Frisoni, GB; Perani, D; Bastianello, S; Bernardi, G; Porteri, C; Boccardi, M; Cappa, SF; Trabucchi, Marco; Padovani, Alessandro.

In: Neurobiology of Aging, Vol. 52, No. 4, 2017, p. 119-131.

Research output: Contribution to journalArticle

@article{93e72dcd1b294a26b126250fa6183830,
title = "Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap",
abstract = "Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries. {\circledC} 2016 Elsevier Inc.",
author = "GB Frisoni and D Perani and S Bastianello and G Bernardi and C Porteri and M Boccardi and SF Cappa and Marco Trabucchi and Alessandro Padovani",
year = "2017",
doi = "10.1016/j.neurobiolaging.2016.02.033",
language = "English",
volume = "52",
pages = "119--131",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap

AU - Frisoni, GB

AU - Perani, D

AU - Bastianello, S

AU - Bernardi, G

AU - Porteri, C

AU - Boccardi, M

AU - Cappa, SF

AU - Trabucchi, Marco

AU - Padovani, Alessandro

PY - 2017

Y1 - 2017

N2 - Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries. © 2016 Elsevier Inc.

AB - Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries. © 2016 Elsevier Inc.

U2 - 10.1016/j.neurobiolaging.2016.02.033

DO - 10.1016/j.neurobiolaging.2016.02.033

M3 - Article

VL - 52

SP - 119

EP - 131

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 4

ER -